Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1

Conditions

Lymphoma, Large-Cell, Anaplastic 3Neuroblastoma 2Carcinoma, Non-Small-Cell Lung 2Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma, Alveolar 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Granuloma, Plasma Cell 1Adenocarcinoma of Lung 1

Interventions

Doxorubicin 4Ifosfamide 3Trabectedin 2perifosine 1indolepropanol phosphate 1fludarabine 1brostallicin 1X-Rays 1Watchful Waiting 1Radiotherapy, Conformal 1Radiotherapy 1Observation 1Mass Spectrometry 1Imatinib Mesylate 1Filgrastim 1Cyclophosphamide 1Crizotinib 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Sarcoma, Alveolar Soft Part × Crizotinib × Clear all
NCT01524926 2023-12-11

CREATE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
582 enrolled
LymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Sarcoma, Clear Cell, Rhabdomyosarcoma, Alveolar, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡